Gabriela Ivankovich-Escoto

Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6-17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial.

BACKGROUND Pertussis remains an important public health issue, in part because current vaccines fail to induce potent mucosal immunity against the causative agent, Bordetella pertussis. In contrast, the live attenuated vaccine BPZE1 induces robust nasal secretory IgA (S-IgA) and protects against B pertussis infection i...